The Vetr crowd upgraded their ratingforJazz Pharmaceuticals plc (NASDAQ: JAZZ) on Thursday, from 3 stars (Hold), issued two days ago, to 4 stars (Buy). At the time of the upgrade, crowd sentiment for the stock was mostly positive, with 83 percent of Vetr user ratings bullish.
Vetr's upgrade for the pharmaceutical company comes off of an analyst initiation from Evercore, who put the stock at Buy. The bullish initiation caused a brief spike of nearly 1.5 percent to $136.91 at today's open. The stock retreated back below the $136 mark to finish the day at 135.32.
Jazz's share price reached a six-month high of $138.66 earlier in the month. The company is expected to report Q4 earnings at the end of February.
See how crowdsourced ratings could help you time the market.
Currently, the Vetr crowd's average target price for Jazz is up at $147.48, which is still below the average analyst target price of $180.29. Less than 2 percent of Vetr users are holding JAZZ in their watch lists.
Latest Ratings for JAZZ
|Feb 2017||Evercore ISI Group||Initiates Coverage On||Buy|
|Dec 2016||Cantor Fitzgerald||Initiates Coverage On||Overweight|
|Aug 2016||Janney Capital||Initiates Coverage on||Neutral|
View More Analyst Ratings for JAZZ
View the Latest Analyst Ratings
See more from Benzinga
- Welcome To Trumpville: The Market In 1929 And Now
- Alphabet's Steady February Gains Prompts Vetr Crowd To Sell
- Vetr Drops Weight Watchers To A Strong Sell
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.